Chemomab Q1 2023 net loss widens to $8.8 million; cash runway extended to H1 2024
Chemomab Therapeutics reported a first-quarter 2023 net loss of $8.8 million, up from $5.1 million a year earlier, driven mainly by higher research and development spending. Cash, cash equivalents and short-term deposits fell to $32.8 million at March 31, 2023, from $39.9 million at December 31, 2022, and the company said its estimated cash runway now extends through the first half of 2024.
Key points
- Net loss was $8.8 million, or about $0.04 per share, versus $5.1 million, or about $0.02 per share, in the first quarter of 2022.
- R&D expenses were $6.9 million versus $2.7 million a year earlier, primarily due to increased clinical and preclinical activities.
- Cash, cash equivalents and short-term bank deposits were $32.8 million at March 31, 2023, compared with $39.9 million at December 31, 2022.
- Estimated cash runway was extended through the first half of 2024; the CM-101 Phase 2 PSC trial top-line data are expected in the second half of 2024.
The filing
Written by AI on Nov 9, 2026, 8:38 AM ET, from this filing only. Written later: this filing was briefed after the fact, when past filings were added to the site, so the brief may be read with hindsight; the filing itself is the record of what was known on May 11, 2023.
Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.